| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.0028 | 1 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.0036 | 1 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.0014 | 1 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0015 | 1 |